Contrave is a fixed combination of naltrexone plus bupropion, specifically FDA-approved for chronic weight management when combined with lifestyle changes
If anything, ongoing users report improvements in baseline digestive function, including more regular bowel movements, less bloating from meals in general, and better tolerance of diverse foods
Research from KFF shows several states that briefly covered GLP-1s have since rolled back benefits under budget pressure, leaving coverage uneven across the country and underscoring the affordability concerns raised in the Louisiana debate
The weight response also tends to return, which is reassuring for anyone who regained during the gap
Our healthcare professionals closely supervise patients between treatments to ensure patient safety and support
These drugs have attracted significant attention in both medical communities and the general public